SCHEMBL2814487

SCHEMBL2814487

COc1ccc(CCNc2nc3c4c(nn(C)c4n2)CCN3Cc2ccc(OC)cc2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCDIN3D Q7Z5W3 3/20 0.40
TP53 P04637 2/20 0.39
ADORA3 P0DMS8 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
SMN1; SMN2 Q16637 3/20 0.38
TSHR P16473 3/20 0.38
GAA P10253 2/20 0.38
HTT P42858 2/20 0.38
MEN1 O00255 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
HRH1 P35367 1/20 0.38
HRH4 Q9H3N8 1/20 0.38
SHMT2 P34897 1/20 0.37
CYP3A4 P08684 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809534 0.95 MAPT (0.40) BCDIN3DTP53ADORA3SMN1; SMN2TSHR
SCHEMBL2809950 0.94 BCDIN3D (0.38) BCDIN3DTP53ADORA3ADORA2AADORA1
SCHEMBL2810910 0.94 ADORA3 (0.44) BCDIN3DADORA3ADORA2AADORA1SMN1; SMN2
SCHEMBL2810448 0.92 BCDIN3D (0.42) BCDIN3DTP53SMN1; SMN2TSHRGAA
SCHEMBL2812452 0.92 TP53 (0.41) BCDIN3DTP53ADORA3ADORA2AADORA1
SCHEMBL2814364 0.90 OGA (0.38) BCDIN3DSMN1; SMN2MEN1KMT2AHRH1
SCHEMBL13131652 0.90 SHMT2 (0.48) BCDIN3DGAAMEN1MAPTKMT2A
SCHEMBL13145613 0.88 BCDIN3D (0.35) BCDIN3DSMN1; SMN2TSHRGAAHTT
SCHEMBL2812793 0.87 HRH1 (0.47) BCDIN3DMEN1MAPTKMT2ANPSR1
SCHEMBL2809862 0.87 PIK3CA (0.47) SMN1; SMN2TSHRHTTMEN1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
WO-2010114905-A1 PERI-FUSED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 BCDIN3D 1422/4885TP53 3/4885ADORA3 614/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.